Effects of Leucovorin (folinic Acid) in the Methotrexate-treated Rat Brain

Overview

Journal J Vet Med Sci

Specialty Veterinary Medicine

Date 2018 Apr 3

PMID 29607891

Authors

Naofumi Ogushi

Kazuaki Sasaki

Minoru Shimoda

Affiliations

Soon will be listed here.

Abstract

Folinic acid (FA) is generally administered to patients with CNS tumors in order to treat severe neurological disorders caused by methotrexate (MTX); therefore, we herein examined the effects of the co-administration of FA on MTX concentrations in the rat brain and cerebrospinal fluid (CSF) as well as the pharmacokinetics of MTX. MTX was intravenously or intrathecally administered to rats with or without FA. MTX concentrations were assessed by HPLC. No significant differences were observed in pharmacokinetic parameters, including k, V, AUC, Cl and t, between the FA-treated and non-treated groups. MTX concentrations were not significantly different in the brain or CSF 6 hr after the intrathecal administration of MTX. However, compare to intravenous administration of MTX, intravenous administration of both FA and MTX significantly decreased MTX concentrations in the brains and CSF. These results suggest that FA inhibits the influx of MTX into the brain and CSF, possibly by competing with folate carriers, but has no effect on its efflux from these regions. Therefore, FA may be administered to CNS tumor patients receiving intrathecal MTX therapy in order to treat the adverse effects of MTX without affecting its concentrations in the brain and CSF.

References

Zhao R, Goldman I . The proton-coupled folate transporter: physiological and pharmacological roles. Curr Opin Pharmacol. 2014; 13(6):875-80. PMC: 4100332. DOI: 10.1016/j.coph.2013.09.011. View

Ogushi N, Sasaki K, Shimoda M . CAN a P-gp modulator assist in the control of methotrexate concentrations in the rat brain? -inhibitory effects of rhodamine 123, a specific substrate for P-gp, on methotrexate excretion from the rat brain and its optimal route of administration. J Vet Med Sci. 2016; 79(2):320-327. PMC: 5326937. DOI: 10.1292/jvms.16-0315. View

Ghersi-Egea J, Strazielle N . Brain drug delivery, drug metabolism, and multidrug resistance at the choroid plexus. Microsc Res Tech. 2001; 52(1):83-8. DOI: 10.1002/1097-0029(20010101)52:1<83::AID-JEMT10>3.0.CO;2-N. View

Genoni S, Palus V, Eminaga S, Cherubini G . Safety of intrathecal administration of cytosine arabinoside and methotrexate in dogs and cats. Vet Comp Oncol. 2014; 14(3):331-6. DOI: 10.1111/vco.12109. View

Bleyer W, Poplack D . Prophylaxis and treatment of leukemia in the central nervous system and other sanctuaries. Semin Oncol. 1985; 12(2):131-48. View

Bhojwani D, Sabin N, Pei D, Yang J, Khan R, Panetta J . Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol. 2014; 32(9):949-59. PMC: 3948096. DOI: 10.1200/JCO.2013.53.0808. View

Wang X, Cabrera R, Li Y, Miller D, Finnell R . Functional regulation of P-glycoprotein at the blood-brain barrier in proton-coupled folate transporter (PCFT) mutant mice. FASEB J. 2012; 27(3):1167-75. PMC: 3574287. DOI: 10.1096/fj.12-218495. View

Serlin Y, Shelef I, Knyazer B, Friedman A . Anatomy and physiology of the blood-brain barrier. Semin Cell Dev Biol. 2015; 38:2-6. PMC: 4397166. DOI: 10.1016/j.semcdb.2015.01.002. View

Kamps W, Bokkerink J, Hahlen K, Hermans J, Riehm H, Gadner H . Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM-86 without cranial radiotherapy: results of Dutch Childhood Leukemia Study Group Protocol ALL-7 (1988-1991). Blood. 1999; 94(4):1226-36. View

10.

Abelson H, Kufe D, SKARIN A, Major P, Ensminger W, Beardsley G . Treatment of central nervous system tumors with methotrexate. Cancer Treat Rep. 1981; 65 Suppl 1:137-40. View

11.

Kaleita T, Reaman G, Maclean W, Sather H, Whitt J . Neurodevelopmental outcome of infants with acute lymphoblastic leukemia: a Children's Cancer Group report. Cancer. 1999; 85(8):1859-65. DOI: 10.1002/(sici)1097-0142(19990415)85:8<1859::aid-cncr28>3.0.co;2-2. View

12.

Zhao R, Diop-Bove N, Visentin M, Goldman I . Mechanisms of membrane transport of folates into cells and across epithelia. Annu Rev Nutr. 2011; 31:177-201. PMC: 3885234. DOI: 10.1146/annurev-nutr-072610-145133. View

13.

Halwachs S, Lakoma C, Schafer I, Seibel P, Honscha W . The antiepileptic drugs phenobarbital and carbamazepine reduce transport of methotrexate in rat choroid plexus by down-regulation of the reduced folate carrier. Mol Pharmacol. 2011; 80(4):621-9. DOI: 10.1124/mol.111.072421. View

14.

Glantz M, Cole B, Recht L, Akerley W, Mills P, Saris S . High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?. J Clin Oncol. 1998; 16(4):1561-7. DOI: 10.1200/JCO.1998.16.4.1561. View

15.

Zeng H, Chen Z, Belinsky M, Rea P, Kruh G . Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001; 61(19):7225-32. View

16.

Reiter A, Schrappe M, Tiemann M, Ludwig W, Yakisan E, Zimmermann M . Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. Blood. 1999; 94(10):3294-306. View

17.

Wolburg H, Paulus W . Choroid plexus: biology and pathology. Acta Neuropathol. 2009; 119(1):75-88. DOI: 10.1007/s00401-009-0627-8. View

18.

Ogushi N, Sasaki K, Shimoda M . Effect of cyclosporin on distribution of methotrexate into the brain of rats. J Vet Med Sci. 2015; 77(9):1171-3. PMC: 4591162. DOI: 10.1292/jvms.14-0671. View

19.

Matherly L, Hou Z . Structure and function of the reduced folate carrier a paradigm of a major facilitator superfamily mammalian nutrient transporter. Vitam Horm. 2008; 79:145-84. PMC: 3806226. DOI: 10.1016/S0083-6729(08)00405-6. View

20.

Soontornmalai A, Vlaming M, Fritschy J . Differential, strain-specific cellular and subcellular distribution of multidrug transporters in murine choroid plexus and blood-brain barrier. Neuroscience. 2005; 138(1):159-69. DOI: 10.1016/j.neuroscience.2005.11.011. View